12:00 AM
Aug 29, 2011
 |  BC Week In Review  |  Company News  |  Other News

Abbott, AstraZeneca infectious news

AstraZeneca's MedImmune LLC subsidiary filed suit in the U.S. District Court for the District of Maryland against Abbott alleging the pharma breached a 2005 deal by declining to submit ex-U.S. regulatory applications for respiratory syncytial virus (RSV) candidate motavizumab. Abbott also has claimed that MedImmune is in breach of contract by refusing to agree to Abbott's decision to discontinue ex-U.S. development of motavizumab. Abbott has ex-U.S. marketing rights to the humanized RSV antibody from MedImmune,...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >